Skip to main content

 Related scientific articles (all)

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Authors : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 860-7

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

Authors : Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, Birnbaum D, Penault-Llorca F
Year : 2013
Journal : Ann Oncol
Volume : 24(3)
Pages : 625-32

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer.

Authors : Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S
Year : 2013
Journal : Clin Cancer Res
Volume : 19(1)
Pages : 28-33

Distinct tumor protein p53 mutants in breast cancer subgroups.

Authors : Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H
Year : 2013
Journal : Int. J. Cancer
Volume : 132(5)
Pages : 1227-31

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Authors : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Year : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pages : R86

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Authors : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Year : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Authors : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Year : 2012
Journal : Oncogene
Volume : 31(31)
Pages : 3569-83

Expression profiling in: WHO Classification of Tumours of the Breast, (Chapter 1: Invasive Breast Carcinoma: introduction and general features) Chapter book : (IARC, 4th edition, 2012)

Authors : Van de Vijver MJ, Hayes D, Perou C, Sotiriou C, Reis LO
Year : 2012
Journal : Book
Volume : 4th edition
Pages : 29-31

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Authors : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Year : 2012
Journal : Breast
Volume : 21(1)
Pages : 20-6

Préface, in de Cremoux P. (Ed): Signatures moléculaires des cancers. L’Innovation thérapeutique en cancérologie - Chapter book (John Libey Eurotext, 2012)

Authors : Sotiriou C
Year : 2012
Journal : Book
Volume : 6
Pages : VII-VIII

The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study.

Authors : Azim HA, Botteri E, Renne G, Dell orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart-Gebhart M, Goldhirsch A, Viale G, Peccatori F
Year : 2012
Journal : Acta oncol (Stockholm)
Volume : 51(5)
Pages : 653-61

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Authors : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Year : 2012
Journal : Ann Oncol
Volume : 23(12)
Pages : 2997-3006

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.

Authors : Ignatiadis M, Sotiriou C, Pantel K
Year : 2012
Journal : Recent Results Cancer Res.
Volume : 195
Pages : 3-9

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Authors : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Year : 2012
Journal : Ann Oncol
Volume : 23
Pages : 2997-3006

Understanding the biology of triple-negative breast cancer.

Authors : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi13-vi18

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Authors : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Year : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pages : e240-8